Matthew Falagas MD, MSc, DSc

PUBLICATIONS: EDITORIALS/COMMENTARIES (PEER-REVIEWED)

 
  1. Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety tigecycline: focus on use for approved indications. Clin Infect Dis (in press).
  2. Falagas ME, Rafailidis PI. Colistin in ventilator-associated pneumonia. Clin Infect Dis 2012;54:681-3.
  3. Chen LF, Falagas ME, Peleg AY. Facing the Rising Tide of Multidrug Resistant Gram-Negative Pathogens. Healthcare Infect 2011;16:1–5.
  4. Falagas ME, Tassios PT. Enhanced and earlier detection of bacteremia and fungemia by multiplex PCR: how much enhanced, how much earlier, and at what cost? Crit Care Med 2008;36:1660-1.
  5. Karamanis EM, Peppas G, Alexiou VG, Falagas ME. World Wide Web resources on prevention and treatment of postoperative infections. Am J Surg 2008;196:307-10.
  6. Peppas G, Alexiou VG, Falagas ME. Bowel cleansing before bowel surgery: major discordance between evidence and practice. J Gastrointent Surg 2008;12:919-20.
  7. Pappas G, Kiriaze IJ, Falagas ME. Insights into infectious disease in the era of Hippocrates. Int J Infect Dis 2008 Jan 4; [Epub ahead of print].
  8. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK. Heteroresistance: a concern of increasing clinical significance? Clin Microbiol Infect 2008;14:101-4.
  9. Vrachliotis T, Falagas ME. Infections after endovascular coiling. J Endovasc Ther 2007;14:805-6.
  10. Trompoukis C, German V, Falagas ME. From the roots of parasitology: Hippocrates’ first scientific observations in helminthology. J Parasitol 2007;93:970-2.
  11. Falagas ME, Alexiou VG. Editors may inappropriately influence authors’ decisions regarding selection of references in scientific articles. Int J Impot Res 2007;19:443-5.
  12. Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 2007;11:134.
  13. Falagas ME, Pitsouni EI. Guidelines and concesus statements regarding the conduction and reporting of clinical research studies. Arch Intern Med 2007;167:877-8.
  14. Falagas ME. Peer review in open access journals. Open Medicine 2007;1:49-51.
  15. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 2007;13:117-9.
  16. Falagas ME, Bliziotis IA. Cost-effectiveness of various research designs: an overlooked parameter in clinical research. J Clin Epidemiol 2007;60:215-6.
  17. Siempos II, Fragoulis KN, Falagas ME. World Wide Web resources on control of nosocomial infections. Crit Care 2007;11:101.
  18. Falagas ME, Rosmarakis ES. Clinical decision-making based on findings presented in conference abstracts: is it safe for our patients? Eur Heart J 2006;27:2038-9.
  19. Falagas ME, Vardakas KZ. Anti-cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients. Clin Microbiol Infect 2006;12:603-5.
  20. Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006;367:633-34.
  21. Papagelopoulos PJ, Falagas ME. Editorial comment on spinal infections. Clin Orthop Relat Res 2006;444:2-3.
  22. Papadimitropoulos V, Vergidis PI, Bliziotis I, Falagas ME. Vaccination against typhoid fever in travelers: a cost-effectiveness approach. Clin Microbiol Infect 2004;10:681-83.
 

PUBLICATIONS: CASE REPORTS (PEER-REVIEWED)

 
  1. Melakopoulos I, Karageorgopoulos DE, Christodoulou C, Skarlos DV, Falagas ME. Tooth and consequences (severe orofacial infection originating from an area of osteonecrosis of the jaw due to bisphosphonate therapy). Am J Med 2008;121:577-9.
  2. German V, Sakagiannis G, Margaritis G, Falagas ME. Inka dinka don’t (shingles on blue skin base). Am J Med 2008;121:772-3.
  3. Rafailidis PI, Kapaskelis A, Christodoulou C, Galani E, Falagas ME. Concurrent M. tuberculosis, Klebsiella pneumoniae, and Candida albicans infection in liver metastasis of bowel carcinoma. Eur J Clin Microbiol Infect Dis 2008 Feb 26. [Epub ahead of print].
  4. Rafailidis PI, Kapaskelis A, Falagas ME. Multifocal Pseudomonas aeruginosa myositis in an apparently healthy adult. Eur J Clin Microbiol Infect Dis 2008;27:159-61.
  5. Falagas ME, Pappas VD, Michalopoulos A. Gangrenous, hemorrhagic, bullous cellulitis associated with Pseudomonas aeruginosa in a patient with Waldenström’s macroglobulinemia. Infection 2007;35:370-3.
  6. Moutzouris D, Manetas S, Mountantonakis SE, Falagas ME. “Please treat me with metoclopramide”. Emerg Med J 2007;24:735-6.
  7. Rafailidis PI, Kapaskelis A, Falagas ME. Cytomegalovirus meningitis in an immunocompetent patient. Med Sci Monit 2007;13:CS107-109.
  8. Rafailidis PI, Kapaskelis A, Falagas ME. Periorbital and facial swelling due to dermatomyositis. CMAJ 2007;176:1580-1.
  9. Moraitou E, Karydis I, Nikita D, Falagas ME. Parodit abscess due to Salmonella enteritidis in an immunocompetent adult. Int J Med Microbiol 2007 Apr;297:123-6.
  10. Athanasiou S, Matthaiou DK, Falagas ME. Vaginal mesh infectiondue to Bacteroides melaninogenicus: a case report of another emerging foreign body related infection. Scand J Infect Dis 2006;38:1108-10.
  11. FalagasME, Siempos II, Tsakoumis I. Cure of persistent, post-appendectomy Klebsiella pneumoniae septicemia with continuous intravenous administration of meropenem. Scand J Infect Dis 2006;38:807-10.
  12. Fragoulis KN, Klouvas GD, Falagas ME. Impetigo-like vegetating nasal lesions caused by Klebsiella pneumoniae. Am J Med 2005;118:925-7.
  13. Michalopoulos A, Falagas ME. Multi-systemic methicillin resistant Staphylococcus aureus (MRSA) community-acquired infection. Med Sci Monit 2006;12:39-43.
  14. ManetasS,  Moutzouris DA, Falagas ME. Scalp necrosis: a rare complication of temporal arteritis. Clin Rheumatol 2007;26:1169.
  15. Vassiloyanakopoulos A, FalagasME, Allamani M, Michalopoulos A. Aspergillus fumigatus tricuspid native valve endocarditis in a non intravenous drug user (IVDU). J Med Microbiol 2006;55:635-8.
  16. Fragoulis KN, Christodoulou C, Falagas ME. Tibia pain and purple-colored lesion. Am J Med 2006;119:835-6.
  17. Bliziotis IA, Kapaskelis AM, Kasiakou SK, Falagas ME. Limitations in the management of aortic graft infections. Annals of Vascular Surgery 2006 Sep;20(5):669-71.
  18. Falagas ME, Bliziotis I, KapaskelisAM. Red streaks on the leg. American Family Physician 2006;73:1061-2.
  19. Bliziotis IA,Kasiakou SK, Kapaskelis AM, Falagas ME. Mesh-related infection after hernia repair: case report of an emerging type of foreign-body related infection. Infection 2006;34:46-8.
  20. Rafailidis PI, Avramopoulos I, SapkasG, Falagas ME. Multidrug-resistant tuberculous spondylodiscitis: need for aggressive management and drug susceptibility testing of Mycobacterium tuberculosis isolates. J  Infect 2006;52:e35-7.
  21. Kasiakou SΚ, Fragoulis K, Tzagarakis G, Mistidis P, Kapaskelis A, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii prosthetic material-related orthopaedic infections with intravenous colistin. Microb Drug Resist2005;11:287-9.
  22. Kasiakou SK,Peppas G,Kapaskelis AM, FalagasME. Regression of skin lesions of Kyrle’s disease with clindamycin: implications for an infectious component in the etiology of the disease. J Infect2005;50:412-6.
  23. Bliziotis I,Rafailidis PI,VergidisP, FalagasME. Regression of subcorneal pustular dermatosis lesions with azithromycin. J Infect2005;51:E31-4.
  24. Bliziotis I, KasiakouS, BaloyanniM, FalagasME. A healthy woman with right upper quadrant discomfort on deep palpation. American Family Physician 2005;71:2353-5.
  25. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. Journal of Infection 2005;50:348-52.
  26. Michalopoulos A, Kasiakou SK, Rosmarakis ES,Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteremia with continuous intravenous infusion of colistin. Scandinavian Journal of Infectious Diseases  2005;37:142-5.
  27. Rizos M, Falagas ME, Tsiodras S, Betsou A, Foukas P, Michalopoulos A. Usual interstitial pneumonia associated with cytomegalovirus infection after percutaneous transluminal coronary angioplasty. Eur J Clin Microbiol Infect Dis 2004;23: 848–50.
  28. Falagas ME, Christopoulou M, RosmarakisES, VlastouC. Munchausen’s syndrome presenting as severe panniculitis. Int J Clin Pract 2004;58:720-2.
  29. Falagas ME, Siakavellas E, Scheib R.  Facial masses. American Family Physician       2000;62: 1619-20.
  30. Falagas ME, Siakavellas E, Sapkas G, Eliadis K, Kontaxis A. Echinococcal cyst of the fifth thoracic vertebra in an otherwise healthy young woman. Clin Infect Dis 2000;30:442-3 and 567-8.
 

 

 

PUBLICATIONS: ORIGINAL RESEARCH - LETTERS TO THE EDITOR (PEER-REVIEWED)

 
  1. Theocharis G, Tansarli GS, Mavros MN, Spiropoulos T, Barbas SG, Falagas ME.Association between use of air-conditioning or fan and survival of elderly febrile patients: a prospective study.Eur J Clin Microbiol Infect Dis. 2013;32:1143-7.
  2. Sahni RD, Balaji V, Varghese R, John J, Tansarli GS, Falagas ME.Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.Future Microbiol. 2013;8:675-80.
  3. Cai Y, Chai D, Falagas ME, Karageorgopoulos DE, Wang R, Bai N, Liang B.Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study.Expert Opin Investig Drugs 2013;22:309-15.
  4. Samonis G, Matthaiou DK, Kofteridis D, Maraki S, Falagas ME. In vitro susceptibility to various antibiotics of colistin resistant Gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin Infect Dis 2010;50:1689-91.
  5. Rosmarakis ES, Papageorgiou PG, Falagas ME. Open-access World Wide Web resources on cardiovascular infections and inflammations. Can J Cardiol 2008;24:e11-5.
  6. Fragoulis KN, Michalopoulos A, Falagas ME. Open access World Wide Web resources on sepsis. Clin Infect Dis 2008;47:588.
  7. Falagas ME, Giannopoulou KP, Issaris EA, Spanos A. World databases of summaries of articles in biomedical fields. Arch Intern Med 2007;167:1204-6.
  8. Papadavid E, Falagas ME. World Wide Web resources of open access, educational dermatology clinical image quizzes and databases. J Am Acad Derm 2007;8:1743-55.
  9. Panos GZ, Lampropoulos KM, Angelousi AG, Charatsis GG, Falagas ME. Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation: a case series analysis. J Clin Gastroenterol 2007;41:222-223.
  10. FalagasME, ZouglakisGM, Papastamataki PA. Trends of the impact factor of scientific journals. Mayo Clin Proc 2006;81:1401-2.
  11. Michalopoulos A, Gregoriades K, Falagas ME. Effect of different arrangements of T-piece parts on oxygenation of patients with tracheostomy. Anesth Analg 2006;103:1054-5.
  12. Falagas ME, ZouglakisGM, KavvadiaPK. How masked is the “masked peer-review”
 

      of abstracts submitted to international medical conferences? Mayo Clin Proc 2006;81:705.

 
  1. Michalopoulos A, FalagasME. The ingredients of a successful donation by brain death program in Greece. Am J Transplant 2006;6:642-3.
  2. Michalopoulos A, Prapas S, Falagas ME. The incidence of adult respiratory distress syndrome in patients undergoing off-pump coronary artery bypass grafting surgery. Eur J Anaesthesiol 2006;23:80.
  3. Samonis G, Kofteridis DP, Maraki S, Alegakis D, Mantadakis E, Papadakis JA, Gikas A, Falagas ME. Levofloxacin and moxifloxacin increase the human gut colonization by Candida species. Antimicrob Agents Chemother 2005;49:5189.
  4. Kondilis BK, Soteriades ES, Falagas ME. Health literacy research in Europe: a snapshot.Eur J Public Health2006;16:113.
  5. Falagas ME, Fabritsi E, Chelvatzoglou FC, Rellos K.Penetration of the English language in science: the case of a German national interdisciplinary critical care conference. Criti Care 2005;9:655-6.
  6. Falagas ME, Fragoulis KN, Kopterides P. An analysis of the published Massachusetts General Hospital case records (1994 –2004). Am J Med 2005;118:1452-3.
 

PUBLICATIONS: META-ANALYSIS - LETTERS TO THE EDITOR (PEER-REVIEWED)

 
  1. Siempos II, Falagas ME. Oral decontamination with chlorhexidine reduces the incidence of nosocomial pneumonia. Crit Care 2006;10:R173.
  2. FalagasME, AngelousiAG, PeppasG. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006;55:537-8.
  3. Falagas ME, and Vardakas KZ. Liposomal amphotericin B as antifungal prophylaxis in bone marrow transplant patients. Am J Hematol 2006;81:299-300.
 

PUBLICATIONS: SYSTEMATIC REVIEW - LETTERS TO THE EDITOR (PEER-REVIEWED)

 
  1. Falagas ME, Matthaiou DK, Rafailidis PI, Panos G, Pappas G. Worldwide prevalence of head lice. Emerg Infect Dis 2008;14:1493-4.
 

 

 

PUBLICATIONS: CASE REPORT - LETTERS TO THE EDITOR (PEER-REVIEWED)

 
  1. Rafailidis PI, Kapaskelis A, Falagas ME. Henoch-Schönlein purpura associated with Proteus mirabilis urinary tract infection. J Am Acad Dermatol 2008 May;58(5 Suppl 1):S98-9.
  2. Falagas ME, Bliziotis IA, Rafailidis PI, Peppas G. Peripheral T-cell lymphoma masquerading as infectious cellulitis. Eur J Dermatol 2007;17:166-7.
  3. Peppas G, Fragoulis KN, Falagas ME. Successful conservative management of large splenic infarcts. J  Gastroenterol Hepatol 2007;22:282-3.
  4. Panos G, Kopterides P, Falagas ME.  Hyperlactatemia due to nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Ann Intern Med 2006;145:867-8.
  5. Rosmarakis ES,KapaskelisAM, RafailidisPI, FalagasME.Wegener’s syndrome presenting as unresponsive pulmonary infection. American Family Physician 2005;71:1062-4.
 

 

 

PUBLICATIONS: COMMENT - LETTERS TO THE EDITOR (PEER-REVIEWED)

 
  1. Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Aerosolized antibiotics for VAP: Absence of proof versus proof of absence? Clin Infect Dis (in press).
  2. Falagas ME, Siempos II. Prevention of ventilator associated pneumonia (VAP): possible role of antimicrobials administered via the respiratory tract. Eur Resp J 2008;31:1138-9.
  3. Falagas ME, Karageorgopoulos DE. PDR (pandrug resistance), XDR (extensive drug resistance), and MDR (multidrug resistance) in gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-2.
  4. Siempos II, Ioannidou II, Falagas ME. The difference between “adequate” and “appropriate” antimicrobial treatment. Clin Infect Dis 2008;46:642-4.
  5. Vardakas KZ, Falagas ME. Interpretation of the findings of a cohort study of bacteremic patients with community acquired pneumonia. Chest 2007;132:1715.
  6. Falagas ME, Panos G. Implications of findings of bibliometric analyses in Parasitology. Trends Parasitol 2007;23:12-3.
  7. Falagas ME. Effect of blinded peer review on abstract acceptance. JAMA 2006;296:1230.
  8. FalagasME, Kasiakou SK, Michalopoulos A. Polymyxins: a word of caution for prudent use of valuable “old antibiotics”. Infect Control Hosp Epidemiol 2006;27:995.
  9. Kopterides P, Falagas Potential consequences of the pneumococcal conjugate vaccine. N Engl J Med 2006;355:95.
  10. Falagas ME, Kopterides P, Siempos II.Attributable mortality of Acinetobacter baumannii infections in critically ill patients.Clin Infect Dis 2006;43:389.
  11. Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274-5.
  12. Falagas ME, Kiriaze
  13. FalagasME. Unique author identification number in scientific databases: a suggestion. PLoS Med 2006;3:249.
  14. Falagas ME, Kasiakou SK. Correct use of the term pandrug-resistant (PDR) Gram-negative bacteria. Clin Microbiol  Infect 2005;11:1049-50.
  15. Michalopoulos A, Kasiakou SΚ,Falagas ME. The significance of different formulations of aerosolized colistin. Crit Care 2005;9:417-8.
  16. Falagas ME, Kasiakou SK, Michalopoulos A. Treatment of multidrug-resistant Pseudomonas aeruginosa andAcinetobacter baumannii2005;4:149-50.
  17. Falagas ME, Kasiakou SK, Michalopoulos A. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:1106-7.
  18. Falagas ME, Vergidis PI. Addressing the limitations of structured abstracts. Ann of Intern Med 2004;141:576-7.
  19. Engels EA, Falagas ME, Lau J, Bennish MI. Typhoid fever vaccines. Vaccine 2000;18:1433-4.
  20. Falagas ME.  Monotherapy versus b-lactam/aminoglycoside combination treatment for Gram-negative bacteremia. Antimicrob Agents Chemother 1997; 41:2593-2594.
  21. Snydman DR, Falagas ME. Cytomegalovirus prevention in transplant recipients. Lancet 1996; 347:268-9.
 

PUBLICATIONS: REPLY - LETTERS TO THE EDITOR

 
  1. Mavros MN, Velmahos GC, Falagas ME. Post-operative Fever and Atelectasis: reply. Chest (in press).
  2. Siempos II, Dimopoulos G, Falagas ME. Value of meta-analyses for guiding antimicrobial treatment. Eur Resp J (in press).
  3. Dimopoulos G, Siempos II, Falagas ME. Concomitant use of systemic corticosteroids and antibiotics for acute exacerbations of chronic bronchitis. Chest (in press).
  4. Siempos II, Dimopoulos G, Falagas ME. Language restrictions in study selection for meta-analyses (reply). Eur Resp J (in press).
  5. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ.Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis: reply. Clin Infect Dis . 2013;57:325-7.
  6. Kakisi OK, Karageorgopoulos DE, Falagas ME. An evidence based approach to screening for Hepatitis C infection in patients with psychiatric disorders; to screen or not to screen?: Reply. Psych Serv 2010;61:325-6; author reply 326-7.
  7. Dimopoulos G, Falagas ME. Selection for Candida non-albicans spp after fluconazole use. Anesth Analg 2008;106:523-9.
  8. Rosmarakis ES, Falagas ME. Thiazolidinedione therapy and restenosis after coronary stent implantation. Am Heart J 2007;154:e41; author reply e43.
  9. Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010;38:954-62.
  10. Falagas ME. World databases of summaries of articles in the biomedical fields. Arch Intern Med 2007;167:1204-6.
  11. Falagas ME, Fragoulis KN. Pain and a purple lesion. Am J Med 2007;120:e15; author reply e17.
  12. Falagas ME, Vardakas KZ, Mourtzoukou EG. Sex differences in the incidence and severity of respiratory tract infections. Resp Med 2008; [Epub ahead of print].
  13. Falagas ME. Open access to infectious diseases case-based learning on the Internet. Clin Infect Dis 2008;46:480-481.
  14. Falagas ME, Rosmarakis ES, Prapas SN. Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopulmonary bypass. J Thorac Cardiovasc Surg 2007;133:591.
  15. FalagasME, Kasiakou SK. Continuous intravenous administration of antibiotics. Lancet Infect Dis 2006;6:259-260.
  16. Falagas ME, Matthaiou DK, Bliziotis IA. Aminoglycosides in combination with a β-lactam for the treatment of bacterial endocarditis: authors' response. J Antimicrob Chemother 2006;57:1255-6.
  17. FalagasME, Vardakas KZ, Michalopoulos A. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy - response to Prentice et al. Br J Haematol 2006;132:658-9.
  18. Falagas ME, Bliziotis IA. Effect of aminoglycoside/beta-lactam combination therapy versus beta lactam monotherapy on the emergence of antimicrobial resistance.Clin Infect Dis 2005;41:1543-4.
  19. Falagas ME,Christopoulou M,Rosmarakis ES,Vlastou C. Munchausen's syndrome presenting as severe panniculitis. Intern J Clin Pract 2005;59:505.
  20. Falagas ME, Snydman DR. Cytomegalovirus and mortality of liver transplant recipients in the 1990s. Ann Intern Med 1997;127:412.
 

 

 
PUBLICATIONS: GROUP AUTHORSHIP - ORIGINAL RESEARCH PAPERS (PEER-REVIEWED)
 
  1. Charbonnel B, et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005;48:553–560.
  2. Belcher G, et al. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 2005;22: 973-9.
  3. Betteridge DJ, et al. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48:2477-81.
  4. RodenM, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with type 2 diabetes mellitus. Diabet Med 2005;22:1101-6.
  5. Matthews DR, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2004;21:167-74.
  6. Belcher G, et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004;58: 833-7.
  7. Schernthaner G, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76.
  8. Charbonnel B, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104.
  9. Bouza E, et al. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). Clin Microbiol Infect 2001;7:532-42.
  10. Bouza E, e al. A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). Clin Microb Infect 2001;7:523-31.
 

PUBLICATIONS: NON PEER-REVIEWED PAPERS

 
  1. Michalopoulos A, Falagas ME. Current therapeutic strategies for Acinetobacter baumannii. Eur Infect Dis (in press).
  2. Dimopoulos G, Falagas ME. Gram-negative bacilli: resistance issues. Eur Infect Dis 2007;1:49-51.
 

 

 

PUBLICATIONS: CONFERENCE REPORT

 
  1. Falagas ME, Karageorgopoulos DK. Antimicrobial resistance in Gram-negative and Gram-positive bacteria -18th ECCMID. IDrugs 2008;11:409-11.
 

back to top

Scientific Director

Matthew E. Falagas
MD, MSc, DSc

- Director, Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece
- Director, 1st Department of Internal Medicine, HYGEIA Hospital
- Adjunct Associate Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts

View CV

Services

Travel Medicine
Travel Medicine
People who travel may be exposed to dangers, which might have an impact on their entertainment or business plans (traveler's diarrhea, jet lag, malaria, yellow…
Inpatient Care
Inpatient Care
We admit our patients to HYGEIA Hospital, a pioneering, private institute, which everyone can trust his/her health. If admission of a patient is required for…
Outpatient Care
Outpatient Care
24 hours/day, 365 days/year availability of scientific staff to help patients.Telephone (210-68.39.600 and 6946-100.000 for emergencies) for easy access to services. 1. Attendance in our…

Academic Activities

Congress Organisation

One of the goals of Alfa HealthCare is to contribute to the organization of high-quality bio-medical conferences in Greece and abroad

Research

In colaboration with AIBE we have many important research programs in the fields of pathology

Εducation

We invest in the education of our medical, scientific, and nursing staff as well as in new medicine methods.

About

Alfa HealthCare S.A. is a medical anonymous company founded in 2002 in Athens, Greece. Our first goal is to provide high quality medical care, in the fields of Internal Medicine and Infectious Diseases. We offer outpatient care, as well as, secondary and tertiary care at the hospital level. ...

Read more

Google Map

Alfa HealthCare Α.Ε.

 

Medical Services
Internal Medicine - Infectious Diseases
9 Neapoleos Str., 151 23 Marousi,
Athens, Greece

Tel.: +30-210-68.39.600
Emergencies: +30-694-61.10.000

Email: info@alfahc.gr

© Copyright 2014 - Design & Development by In-Com. All rights Reserved